Gatuzosiran vs Rapirosiran (ALN-HSD)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: HSD17B13 · full MASH / NASH pipeline
Gatuzosiran
Developed by GlaxoSmithKline and partners
NCT06104319 · Phase 2 · completed
The trial randomized participants among four GSK4532990 dose groups, but it was open-label, had no placebo or active comparator, and used biomarker expression rather than a clinical or endoscopic outcome as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Predicted percent change from baseline in liver biopsy-derived HSD17B13 protein expression levels (Baseline (Day 1) and up to Week 28): Predicted mean change from baseline in HSD17B13 protein expression at Week 28: -26.82% (25 mg), -61.82% (200 mg), -70.02% (400 mg), -75.27% (800 mg)
Result source: NCT06104319
Rapirosiran (ALN-HSD)
Developed by Regeneron Pharmaceuticals and partners
NCT04565717 · Phase 1 · terminated
This randomized, double-blind, placebo-controlled Phase 1 study (ALN-HSD-001) gave single ascending doses of rapirosiran (ALN-HSD) or placebo to 58 healthy adults and two doses 12 weeks apart to 46 adults with MASH. Its primary endpoint was the frequency of adverse events, with no efficacy hypothesis, so there is no met or missed result. There were no treatment-related serious adverse events and no drug-induced liver injury, and liver HSD17B13 mRNA fell by a median 78% at 6 months at the highest dose. The registry lists only 6 participants and posts no results; the figures come from the peer-reviewed paper (J Hepatol 2025), which names this registration.
The registry lists 6 participants (terminated) and posts no results; the published paper (J Hepatol 2025, PMID 40581300) reports 58 healthy adults in Part A and 46 adults with MASH in Part B.
Next expected readout: April 2028 · NCT05519475 (registry estimate)
Reported efficacy
Parts A and B: Frequency of Adverse Events (Part A: Up to 3.5 months; Part B: up to 12.5 months); Part C: Change from Baseline of Liver Hydroxysteroid 17β Dehydrogenase 13 (HSD17B13) Messenger Ribonucleic Acid (mRNA) (Baseline and Month 6): Primary outcome, safety (no formal efficacy test): no treatment-related serious adverse events and no evidence of drug-induced liver injury in Part A (58 healthy adults) or Part B (46 adults with MASH). Secondary: dose-dependent reduction in liver HSD17B13 mRNA, median 78% at 6 months at 400 mg (J Hepatol 2025). (not_applicable)
Result source: NCT04565717
Results for MASH / NASH
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Gatuzosiran | Rapirosiran (ALN-HSD) |
|---|---|---|
| MASH resolution without fibrosis worsening | —Not reported | —Not reported |
| Fibrosis stage, change | —Not reported | —Not reported |
| Liver fat (MRI-PDFF), change | —Not reported | —Not reported |
| ALT, change | —Not reported | —Not reported |
MASH resolution without fibrosis worsening
- Gatuzosiran
- —Not reported
- Rapirosiran (ALN-HSD)
- —Not reported
Fibrosis stage, change
- Gatuzosiran
- —Not reported
- Rapirosiran (ALN-HSD)
- —Not reported
Liver fat (MRI-PDFF), change
- Gatuzosiran
- —Not reported
- Rapirosiran (ALN-HSD)
- —Not reported
ALT, change
- Gatuzosiran
- —Not reported
- Rapirosiran (ALN-HSD)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Rapirosiran (ALN-HSD): no structured comparison results are available for MASH / NASH.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Gatuzosiran: 3 of 4 rows · Rapirosiran (ALN-HSD): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Gatuzosiran |
|---|---|
| Dropout rate | 0%200 mga NCT04202354 · Phase 1/2 · monotherapy show 6 more results0%200 mg NCT04202354 · Phase 1/2 · monotherapy 0%100 mg NCT04202354 · Phase 1/2 · monotherapy 0%100 mg NCT04202354 · Phase 1/2 · monotherapy 0%50 mg NCT04202354 · Phase 1/2 · monotherapy 0%25 mg NCT04202354 · Phase 1/2 · monotherapy 0%25 mg NCT04202354 · Phase 1/2 · monotherapy |
| Discontinued due to AEs | —200 mga NCT04202354 · Phase 1/2 · monotherapy show 6 more results—200 mg NCT04202354 · Phase 1/2 · monotherapy —100 mg NCT04202354 · Phase 1/2 · monotherapy —100 mg NCT04202354 · Phase 1/2 · monotherapy —50 mg NCT04202354 · Phase 1/2 · monotherapy —25 mg NCT04202354 · Phase 1/2 · monotherapy —25 mg NCT04202354 · Phase 1/2 · monotherapy |
| Serious AEs | 0%200 mga NCT04202354 · Phase 1/2 · monotherapy show 6 more results16.7%200 mg NCT04202354 · Phase 1/2 · monotherapy 0%100 mg NCT04202354 · Phase 1/2 · monotherapy 0%100 mg NCT04202354 · Phase 1/2 · monotherapy 0%50 mg NCT04202354 · Phase 1/2 · monotherapy 0%25 mg NCT04202354 · Phase 1/2 · monotherapy 0%25 mg NCT04202354 · Phase 1/2 · monotherapy |
| Most frequent reported AEs | 200 mga injection site erythema 50% (placebo 0%) injection site swelling 25% (placebo 0%) mouth ulceration 25% (placebo 0%) NCT04202354 · Phase 1/2 · monotherapy show 6 more results200 mg arthralgia 16.7% (placebo 0%) chest pain 16.7% (placebo 0%) eye injury 16.7% (placebo 0%) NCT04202354 · Phase 1/2 · monotherapy 100 mg abdominal discomfort 25% (placebo 0%) blepharospasm 25% (placebo 0%) diarrhea 25% (placebo 0%) NCT04202354 · Phase 1/2 · monotherapy 100 mg blood creatine phosphokinase increased 16.7% (placebo 0%) dermatitis contact 16.7% (placebo 0%) headache 16.7% (placebo 0%) NCT04202354 · Phase 1/2 · monotherapy 50 mg medical device site reaction 25% (placebo 6.3%) productive cough 25% (placebo 0%) abdominal discomfort 0% (placebo 0%) NCT04202354 · Phase 1/2 · monotherapy 25 mg dental caries 25% (placebo 0%) injection site bruising 25% (placebo 0%) nausea 25% (placebo 0%) NCT04202354 · Phase 1/2 · monotherapy 25 mg arthralgia 16.7% (placebo 0%) dental caries 16.7% (placebo 0%) diarrhea 16.7% (placebo 0%) NCT04202354 · Phase 1/2 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gatuzosiran's landscape · Rapirosiran (ALN-HSD)'s landscape